{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:58:56Z","timestamp":1782712736277,"version":"3.54.5"},"reference-count":6,"publisher":"Mattioli1885","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.5826\/dpc.1501a4893","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T11:38:48Z","timestamp":1737459528000},"page":"4893","source":"Crossref","is-referenced-by-count":7,"title":["Real-life Experience of Bimekizumab in 27 Obese Patients With Plaque-type Psoriasis: a 24-week Multicenter Retrospective Study"],"prefix":"10.5826","volume":"15","author":[{"given":"Zeno","family":"Fratton","sequence":"first","affiliation":[{"name":"Institute of Dermatology, Department of Medicine, University of Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Maione","sequence":"additional","affiliation":[{"name":"Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bighetti","sequence":"additional","affiliation":[{"name":"Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bettolini","sequence":"additional","affiliation":[{"name":"Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Stinco","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Department of Medicine, University of Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Errichetti","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Department of Medicine, University of Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"10.5826\/dpc.1501a4893_ref1","doi-asserted-by":"crossref","unstructured":"Megna M, Di Costanzo L, Argenziano, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19:855\u2013861. DOI: 10.1080\/14712598.2019.1622678. PMID: 31140882.","DOI":"10.1080\/14712598.2019.1622678"},{"key":"10.5826\/dpc.1501a4893_ref2","doi-asserted-by":"crossref","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1196966. DOI: 10.3389\/fmed.2023.1196966. PMID: 37469659.","DOI":"10.3389\/fmed.2023.1196966"},{"key":"10.5826\/dpc.1501a4893_ref3","doi-asserted-by":"crossref","unstructured":"Galluzzo M, Marcelli L, Vellucci L, et al. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. Expert Opin Biol Ther. 2023;23:371\u2013381. DOI: 10.1080\/14712598.2023.2194485. PMID: 36971507.","DOI":"10.1080\/14712598.2023.2194485"},{"key":"10.5826\/dpc.1501a4893_ref4","doi-asserted-by":"crossref","unstructured":"Mastorino L, Susca S, Megna M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022;35. DOI: 10.1111\/dth.15378. PMID: 35156278.","DOI":"10.1111\/dth.15378"},{"key":"10.5826\/dpc.1501a4893_ref5","doi-asserted-by":"crossref","unstructured":"Wang J, Yu Y, Liu L, et al. Global prevalence of obesity in patients with psoriasis: An analysis in the past two decades. Autoimmun Rev. 2024 Jun;23(6):103577. DOI: 10.1016\/j.autrev.2024.103577. PMID: 39009055.","DOI":"10.1016\/j.autrev.2024.103577"},{"key":"10.5826\/dpc.1501a4893_ref6","doi-asserted-by":"crossref","unstructured":"Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1243843. DOI: 10.3389\/fmed.2023.1243843. PMID: 37614958.","DOI":"10.3389\/fmed.2023.1196966"}],"container-title":["Dermatology Practical & Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4893\/2991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4893\/3466","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4893\/2991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:33:16Z","timestamp":1762507996000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/4893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":6,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1501a4893","relation":{"has-manifestation":[{"id-type":"other","id":"1-78-4893-g2991","asserted-by":"subject"},{"id-type":"other","id":"1-78-4893-g3466","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.v15i1","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"article-number":"2"}}